gdc

Newsworthy

FDA NewsNewsworthyProstate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Blincyto First Drug Approved for ALL and the MRD Biomarker
Cancer BiomarkersFDA NewsLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
FDA Approves First Direct-to-Consumer Genetic Test for 3 Types of BRCA Mutations in Men and Women
Cancer ScreeningFDA NewsNewsworthy
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
LeukemiaNewsworthyWeb Exclusives
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
Page 1 of 5
Results 1 - 10 of 45

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country